MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug enters first human trial for Tough-to-Treat leukemias
Disease control Recruiting nowThis is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug cocktail tested to fight aggressive blood cancers
Disease control Recruiting nowThis study is testing a combination of five drugs to treat adults newly diagnosed with specific, aggressive forms of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into remission. The treatment involves chemotherapy and a targeted…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First human trial launches for experimental blood cancer drug
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-4098 in adults with advanced forms of blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see how well the drug works when given alone or combined …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug combo aims to control aggressive blood disorder
Disease control Recruiting nowThis study is testing a targeted drug called enasidenib, sometimes combined with another drug (azacitidine), for people with a high-risk type of blood and bone marrow disorder called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New 'Smart Bomb' radiation therapy tested for Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Targeted radiation zaps blood cancer cells before transplant
Disease control Recruiting nowThis study is testing a new treatment for aggressive blood cancers (like leukemia or MDS) that have come back or are not responding to standard therapies. The treatment involves a radioactive antibody designed to seek out and destroy cancer cells, followed by a stem cell transpla…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC